The Company has received initial regulatory approvals in Europe to initiate the ZENITH-1 exploratory clinical trial this summer. Jon Stonehouse, Chief Executive Officer said: "To complement the attractive
The FDA Orphan Drug Designation program provides orphan status to drugs and biologics which are defined as those intended for the safe and effective treatment, diagnoses or prevention
The randomized Phase 2 "YOSEMITE" trial was designed to assess the efficacy and safety of demcizumab plus standard-of-care chemotherapy in first-line metastatic pancreatic cancer with the primary endpoint
The approach is based on the work of Dr. George Miller, Director of S. Arthur Localio Laboratories and Director of the Cancer Immunology Program at NYU School of
Takeda and NuBiyota will collaborate to advance oral microbial consortia products developed by using NuBiyota’s microbiome platform for GI indications. NuBiyota will receive an upfront payment and is
The platform will enable BioCelerate's member companies to aggregate and analyze preclinical and clinical information to improve drug development efficiency and bring new medicines to patients faster. Kevin Julian,
The trial included 60 patients with the mycosis fungoides (MF) variant of CTCL, who were randomized to receive either 0.5% remetinostat gel BID, 1% remetinostat gel QD or
Harvoni was approved for pediatric patients with genotype 1, 4, 5 or 6 chronic HCV infection. Sovaldi was approved for pediatric patients with genotype 2 or 3 chronic
Under the terms of the license agreement, Immune-Onc will acquire the exclusive global rights to develop and commercialize novel biotherapeutics with applications in cancer immunotherapy and other diseases.
The data demonstrated that serum phosphorus levels, rickets, growth rates, and other functional outcomes improved with burosumab, and these treatment effects were sustained through 64 weeks of treatment.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.